Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ketoprofen 10% · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Ketoprofen 10% Cream | ACTIVE_COMPARATOR | Topical Ketoprofen 10% Cream 1gram three times daily for 7 days |
| Placebo | PLACEBO_COMPARATOR | Topical placebo cream 1gram three times daily for 7 days |
| Name | Type | Description |
|---|---|---|
| Topical Ketoprofen 10% Cream | DRUG | Topical Administration |
| Topical Placebo Cream | DRUG | Topical Administration |
Inclusion Criteria: * 18 to 70 years of age * Have a diagnosis of uncomplicated acute soft tissue injury of the upper or lower extremity that has occurred within the 72 hours preceding the baseline visit. * The injury site must be accessible to the patient so that he or she can apply the study trea...
Ketoprofen 10% is a topical cream being developed for the treatment of pain associated with mild to moderate acute soft tissue injury, including sprains and strains. It is a small molecule drug currently in Phase 3 clinical development.
Ketoprofen 10% is being developed by Harrow, Inc. (NASDAQ: HROW). The company is conducting clinical trials to evaluate the drug's safety and efficacy for treating pain from acute soft tissue injuries.
Ketoprofen 10% is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 3 trial has been completed to assess its use for pain associated with mild to moderate acute soft tissue injury.
Ketoprofen 10% has one completed Phase 3 trial, NCT00765700, titled 'Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury.' The trial enrolled 364 participants in the United States and was randomized, double-blind, and placebo-controlled.
Ketoprofen 10% is a topical nonsteroidal anti-inflammatory drug (NSAID) that works by reducing inflammation and pain at the site of application. It is applied directly to the skin over the injured area to provide localized relief for acute soft tissue injuries.